Equities

MacroGenics Inc

MacroGenics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.47
  • Today's Change-0.21 / -4.49%
  • Shares traded1.01m
  • 1 Year change-26.36%
  • Beta2.0810
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

  • Revenue in USD (TTM)43.36m
  • Net income in USD-23.24m
  • Incorporated2000
  • Employees339.00
  • Location
    MacroGenics Inc9704 Medical Center DriveROCKVILLE 20850United StatesUSA
  • Phone+1 (301) 251-5172
  • Fax+1 (301) 251-5321
  • Websitehttps://www.macrogenics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Poseida Therapeutics Inc82.50m-108.86m267.60m335.00--3.16--3.24-1.18-1.180.89070.87390.2864--8.06250,006.10-37.78-40.70-49.17-47.72-----131.94-233.49---12.880.4096---50.42---92.85--19.01--
Fractyl Health Inc148.00k-83.16m270.14m102.00--3.21--1,825.26-1.73-1.730.00311.76------1,450.98--------37.16---46,270.95--9.37-5.100.2542-------48.15------
Enanta Pharmaceuticals Inc72.88m-131.74m271.94m145.00--1.64--3.73-6.25-6.253.467.840.197--5.70502,627.60-35.60-14.56-40.33-15.62-----180.75-54.96----0.0085---8.07-17.45-9.91--24.89--
MacroGenics Inc43.36m-23.24m279.97m339.00--2.63--6.46-0.3754-0.37540.69691.700.14655.132.00127,896.80-7.85-37.76-9.48-45.5384.28---53.60-133.963.61-96.210.00---61.33-0.460692.44---41.13--
Nature's Sunshine Products Inc447.68m16.54m281.70m814.0017.741.839.450.62920.84790.847922.968.201.861.9144.39549,974.207.336.5710.669.4172.1972.693.943.741.42--0.01327.725.554.073,965.64--16.73--
Sutro Biopharma Inc154.07m-114.96m283.01m300.00--2.20--1.84-1.89-1.892.531.570.4047--7.48510,149.00-30.20-25.48-36.94-29.75-----74.62-113.71----0.00--126.8431.9610.41--22.61--
MeiraGTx Holdings PLC11.38m-74.11m288.74m402.00--2.37--25.37-1.27-1.270.18871.890.0381--0.482127,159.90-24.81-26.40-31.62-32.66-----651.19-420.70---27.540.3729---11.95--35.17--12.37--
Foghorn Therapeutics Inc.33.90m-92.95m290.48m116.00------8.57-2.21-2.210.8046-2.290.108----292,206.90-29.61-31.35-35.75-35.69-----274.23-777.33--------77.63--9.60---4.50--
Scilex Holding Co47.05m-160.60m291.72m106.00------6.20-1.28-1.280.3905-1.790.53075.531.92448,047.60-121.78------66.14---229.47--0.1356-12.49----22.90---614.67------
Inozyme Pharma Inc0.00-77.11m293.20m59.00--2.47-----1.37-1.370.001.920.00----0.00-48.39-45.00-52.50-48.90------------0.2748-------6.13--2.85--
Procaps Group SA414.10m52.20m293.34m5.50k4.997.454.210.70840.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Skye Bioscience Inc0.00-37.50m294.15m11.00--3.73-----4.50-4.500.002.810.00----0.00-75.43-232.67-101.00-------------46.110.0552-------93.23--23.38--
XOMA Corp5.81m-45.09m294.22m13.00--3.57--50.63-3.92-3.920.50537.080.0329--1,291.33447,000.00-22.44-4.55-24.19-4.94-----681.69-31.87---24.550.5944---21.06-2.13-105.10--23.16--
Shattuck Labs Inc2.72m-85.08m294.34m75.00--2.28--108.41-1.93-1.930.06082.710.0168----36,200.00-52.52-29.14-57.94-32.42-----3,133.63-565.33----0.00--154.14-40.6214.37---19.15--
Revance Therapeutics Inc236.65m-313.72m294.54m597.00------1.24-3.61-3.652.71-0.9450.44821.8710.46396,390.30-59.42-55.55-69.02-63.2069.11---132.57-304.964.64-30.791.30--76.55128.849.10---0.3022--
Data as of Jun 14 2024. Currency figures normalised to MacroGenics Inc's reporting currency: US Dollar USD

Institutional shareholders

66.70%Per cent of shares held by top holders
HolderShares% Held
Bellevue Asset Management AGas of 31 Mar 20249.97m15.93%
Avoro Capital Advisor LLCas of 31 Mar 20246.15m9.83%
BlackRock Fund Advisorsas of 31 Mar 20244.79m7.66%
SSgA Funds Management, Inc.as of 31 Mar 20244.39m7.02%
The Vanguard Group, Inc.as of 31 Mar 20243.57m5.70%
Millennium Management LLCas of 03 Jun 20243.21m5.13%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20242.77m4.42%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20242.41m3.85%
Armistice Capital LLCas of 31 Mar 20242.40m3.84%
RA Capital Management LPas of 31 Mar 20242.08m3.33%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.